MetaSite: Understanding Metabolism in Human Cytochromes from the Perspective of the Chemist

Citations Over TimeTop 10% of 2005 papers

Abstract

Identification of metabolic biotransformations can significantly affect the drug discovery process. Since bioavailability, activity, toxicity, distribution, and final elimination all depend on metabolic biotransformations, it would be extremely advantageous if this information could be produced early in the discovery phase. Once obtained, this information can help chemists to judge whether a potential candidate should be eliminated from the pipeline or modified to improve chemical stability or safety of new compounds. The use of in silico methods to predict the site of metabolism in phase I cytochrome-mediated reactions is a starting point in any metabolic pathway prediction. This paper presents a new method, specifically designed for chemists, that provides the cytochrome involved and the site of metabolism for any human cytochrome P450 (CYP) mediated reaction acting on new substrates. The methodology can be applied automatically to all the cytochromes for which 3D structure is known and can be used by chemists to detect positions that should be protected in order to avoid metabolic degradation or to check the suitability of a new scaffold or prodrug. The fully automated procedure is also a valuable new tool in early ADME-Tox assays (absorption, distribution, metabolism, and excretion toxicity assays), where drug safety and metabolic profile patterns must be evaluated as soon, and as early, as possible.

Related Papers

• → Optimization of metabolic stability as a goal of modern drug design(2001)142 cited
• → Early ADME in Support of Drug Discovery: The Role of Metabolic Stability Studies(2000)103 cited
• → Introduction of Drug Metabolism and Overview of Disease Effect on Drug Metabolism(2016)9 cited
• → Prodrugs(2016)4 cited
• → Progress in ADME Prediction Using GRID‐Molecular Interaction Fields(2005)1 cited